Tags

Type your tag names separated by a space and hit enter

Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses.
Int Immunopharmacol. 2020 Sep; 86:106717.II

Abstract

The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This decreases the cost of a vaccine and makes it affordable. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emergingSARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease.

Authors+Show Affiliations

Dr GC Negi College of Veterinary and Animal Sciences, Palampur 176062, Himachal Pradesh, India. Electronic address: dr.tania603@gmail.com.CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32585611

Citation

Gupta, Tania, and Shishir K. Gupta. "Potential Adjuvants for the Development of a SARS-CoV-2 Vaccine Based On Experimental Results From Similar Coronaviruses." International Immunopharmacology, vol. 86, 2020, p. 106717.
Gupta T, Gupta SK. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int Immunopharmacol. 2020;86:106717.
Gupta, T., & Gupta, S. K. (2020). Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. International Immunopharmacology, 86, 106717. https://doi.org/10.1016/j.intimp.2020.106717
Gupta T, Gupta SK. Potential Adjuvants for the Development of a SARS-CoV-2 Vaccine Based On Experimental Results From Similar Coronaviruses. Int Immunopharmacol. 2020;86:106717. PubMed PMID: 32585611.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. AU - Gupta,Tania, AU - Gupta,Shishir K, Y1 - 2020/06/18/ PY - 2020/05/02/received PY - 2020/06/03/revised PY - 2020/06/15/accepted PY - 2020/6/26/pubmed PY - 2020/8/25/medline PY - 2020/6/26/entrez KW - Adjuvant KW - COVID-19 KW - Coronavirus KW - MERS KW - SARS KW - SARS-CoV-2 KW - Vaccine SP - 106717 EP - 106717 JF - International immunopharmacology JO - Int Immunopharmacol VL - 86 N2 - The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This decreases the cost of a vaccine and makes it affordable. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emergingSARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease. SN - 1878-1705 UR - https://www.unboundmedicine.com/medline/citation/32585611/Potential_adjuvants_for_the_development_of_a_SARS_CoV_2_vaccine_based_on_experimental_results_from_similar_coronaviruses_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1567-5769(20)31386-2 DB - PRIME DP - Unbound Medicine ER -